Financial comparisons GC Genome Corporation
Stocks
A340450
KR7340450006
Healthcare Facilities & Services
|
End-of-day quote
Korea S.E.
11/09/2026
|
5-day change | 1st Jan Change | ||
| 5,820.00 KRW | -2.02% |
|
+5.63% | -14.66% |
| 09/12 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/25/12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 230.61Cr | -9.03% | -13.44% | -14.32% | -10.26% | 3.74x | |
| 1.4TCr | 6.28% | 14.35% | 16.52% | 7.49% | 2.1x | |
| 632.36Cr | 5.32% | 9.43% | 6.32% | 3.33% | 1.63x | |
| 204.02Cr | -0.91% | 3.04% | - | - | 1.07x | |
| 29Cr | 18.27% | 22.47% | 21.57% | 17.22% | -1.7x | |
| 43Cr | -4.92% | 9.66% | - | - | - | |
| 150.53Cr | 7.39% | 14.73% | 11.91% | 4.66% | 1.46x | |
| 73Cr | -14.85% | -15.93% | 1.71% | - | - | |
| 86Cr | -2.87% | -2.15% | -2.51% | -1.73% | -4.19x | |
| 8.68Cr | 21.24% | 30.1% | 19.7% | 12.44% | -0.83x | |
| 144.34Cr | 0.44% | 2.79% | 0.68% | 0.29% | 0.58x | |
| 18Cr | 11.55% | 16.23% | 13.36% | 9.49% | -0.11x | |
| 155.57Cr | 2.76% | 1.93% | 5% | 1.04% | 1.01x | |
| 61Cr | -37.19% | -19.34% | -17.14% | -10.92% | 0.19x | |
| 8.84Cr | 19.67% | 24.54% | 29.61% | - | - | |
| 95Cr | 5.16% | 6.94% | 6% | 4.23% | - | |
| 32Cr | 7.56% | 8.76% | 6.49% | 4.36% | - | |
| 55Cr | 2.78% | 12.32% | 6.94% | 3.32% | 1.76x | |
| Average | 190.01Cr | 2.15% | 7.02% | 6.99% | 3.21% | 0.52x | |
| Weighted average by Cap. | 495.01Cr | -1.6% | -0.03% | -0.43% | -1.87% | 2.40x |
- Stock Market
- Stocks
- A340450 Stock
- Sector GC Genome Corporation
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
